New hope for tough hodgkin lymphoma: immune drugs tested alone or together

NCT ID NCT04938232

Ongoing Disease control Sponsor: Dana-Farber Cancer Institute Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests two immune-boosting drugs, ipilimumab and nivolumab, in people with classic Hodgkin lymphoma that has returned or not responded to prior therapy. The goal is to see if giving these drugs alone or together can shrink tumors. The trial involves 13 adults with measurable disease and aims to find better ways to control this cancer.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HODGKIN LYMPHOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

classic Hodgkin lymphoma Hodgkins lymphoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

HODGKIN LYMPHOMA REFRACTORY HODGKIN LYMPHOMA RELAPSED HODGKIN'S DISEASE, ADULT

Contacts and locations

Locations

Brigham and Women's Hospital

Boston, Massachusetts, 02115, United States
Dana-Farber Cancer Institute

Boston, Massachusetts, 02215, United States
Massachusetts General Hospital

Boston, Massachusetts, 02114, United States
University of Chicago Medicine

Chicago, Illinois, 60637, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.